Skip to content
Contactez-nous: (+33) 1 64 62 10 12
Theradiag
  • Home
  • Company
    • About us
    • Our history
    • A word from our CEO
    • Our management team
    • Board of directors
    • Know-how
    • Privacy policy
  • Theranostic
    • Therapeutic Drug Monitoring of Biologics – TRACKER
      • Therapeutic Drug Monitoring of Biologics
        • TDM of Biologics
        • When to perform TDM ?
        • Results interpretation
        • Therapeutic Thresholds
        • Tracker Publications
        • Guidelines
        • Frequently asked questions
      • TRACKER
        • LISA TRACKER
        • I-Tracker
        • i-Track 10
        • Immunotrol Tracker
    • Patient Stratification -PredictImmune
    • American Customers
  • Diagnostics
    • Autoimmunity
      • Reagents – Autoimmunity
      • Quality Control – Auto-Immunity
    • SARS-CoV 2 Serology Testing
    • Other fields
    • Instrumentation
      • Theralis
      • FIDIS™
  • Services
    • Technical Documentation Download Center
  • News
    • Press Releases
    • List of upcoming events
    • Congress calendar
  • Investors
    • Welcome Message
    • Financial News
      • Register to receive our latest news
      • Press Releases
      • Financial Reports
      • Financial presentations
    • Shareholder information
      • Stock information
      • Shareholding
      • Analyst coverage
      • Letters to shareholders
      • General meeting
    • Regulated information
      • Share capital and voting rights
      • Corporate governance & internal control
      • Statutory auditors fees
      • Description of the buyback program
      • Prospectus
      • Share buyback statement
      • Charters and code of ethics / Anti-corruption
      • Other regulated information
    • Governance
      • Board of directors
      • Statute and internal regulations
      • Quiet period policy and trading windows
    • Investor contacts and registration
    • Legal notice
  • Contacts
  • Français
  • English
Menu Close

Governance

  1. Home>
  2. Investors>
  3. Governance

Latest Press Releases

  • 30/03/2022 Evolution of governance
    30 March 2022/
    0 Comments
  • Presentation of the 2021 full year results (only available in french) – 2022, 21st March
    21 March 2022/
    0 Comments
  • 21/03/2022: Theradiag announces its 2021 full-year results
    21 March 2022/
    0 Comments

Events

02 Apr 2022

21st Annual GI Update

19 - 20 May 2022

Annual congress BIO MED J

Palais des Congrès d’Issy les Moulineaux
19 - 20 May 2022

Annual congress BIO MED J

Palais des Congrès d’Issy les Moulineaux
No event found!
Load More

Next financial Event

No event found!

Useful links

  • Diagnostic
  • Theranostic
  • Events
  • Register to receive our latests news

Contact Information

  • Address:14, Rue Ambroise Croizat, 77183 Croissy Beaubourg, France
  • Phone:+33 1 64 62 10 12
  • Email:info@theradiag.comOpens in your application

Follow Us

Theradiag ©
  • Home
  • Company
    • About us
    • Our history
    • A word from our CEO
    • Our management team
    • Board of directors
    • Know-how
    • Privacy policy
  • Theranostic
    • Therapeutic Drug Monitoring of Biologics – TRACKER
      • Therapeutic Drug Monitoring of Biologics
        • TDM of Biologics
        • When to perform TDM ?
        • Results interpretation
        • Therapeutic Thresholds
        • Tracker Publications
        • Guidelines
        • Frequently asked questions
      • TRACKER
        • LISA TRACKER
        • I-Tracker
        • i-Track 10
        • Immunotrol Tracker
    • Patient Stratification -PredictImmune
    • American Customers
  • Diagnostics
    • Autoimmunity
      • Reagents – Autoimmunity
      • Quality Control – Auto-Immunity
    • SARS-CoV 2 Serology Testing
    • Other fields
    • Instrumentation
      • Theralis
      • FIDIS™
  • Services
    • Technical Documentation Download Center
  • News
    • Press Releases
    • List of upcoming events
    • Congress calendar
  • Investors
    • Welcome Message
    • Financial News
      • Register to receive our latest news
      • Press Releases
      • Financial Reports
      • Financial presentations
    • Shareholder information
      • Stock information
      • Shareholding
      • Analyst coverage
      • Letters to shareholders
      • General meeting
    • Regulated information
      • Share capital and voting rights
      • Corporate governance & internal control
      • Statutory auditors fees
      • Description of the buyback program
      • Prospectus
      • Share buyback statement
      • Charters and code of ethics / Anti-corruption
      • Other regulated information
    • Governance
      • Board of directors
      • Statute and internal regulations
      • Quiet period policy and trading windows
    • Investor contacts and registration
    • Legal notice
  • Contacts
  • Français
  • English
We use cookies to ensure the best experience on our website. If you continue to use this site, we will assume that you are satisfied.OkNoLearn more